Screener
BridgeBio Pharma BBIO Income Tax
Income Tax at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:IncomeTaxExpenseBenefit.
The source filing: BridgeBio Pharma’s 10-Q, filed August 10, 2026.
- Filed
- Aug 10, 2026, 4:31 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001743881-26-000027
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Other income, net | 5,587 | 6,548 | 9,840 | 14,779 |
| Total other expense, net | (48,812) | (47,380) | (109,411) | (112,616) |
| Loss before income taxes | (155,891) | (181,658) | (322,446) | (351,266) |
| Provision for income taxes | — | 2,100 | — | 2,100 |
| Net loss | (155,891) | (183,758) | (322,446) | (353,366) |
| Net loss attributable to redeemable convertible noncontrolling interests and noncontrolling interests | 3,675 | 1,855 | 6,187 | 4,041 |
| Net loss attributable to common stockholders of BridgeBio | $(152,216) | $(181,903) | $(316,259) | $(349,325) |
| Net loss per share attributable to common stockholders of BridgeBio, basic and diluted | $(0.78) | $(0.95) | $(1.62) | $(1.84) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's income tax?
- BridgeBio Pharma (BBIO) reported income tax of $0 in Q2 2026.
- How has BridgeBio Pharma's income tax changed year-over-year?
- BridgeBio Pharma's income tax decreased by 100.0% year-over-year, from $2.1M to $0.
- What does income tax mean?
- Total income tax expense (current + deferred) recognized in the income statement, representing the company's total tax obligation on pre-tax income.
Ask your AI about BridgeBio Pharma's income tax.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude